Pan-PPAR Modulation Effectively Protects APP/PS1 Mice from Amyloid Deposition and Cognitive Deficits

Molecular Neurobiology

Volumn 51, Issue 2, 2015, Pages 661-671

  Kummer, Markus P ^a   Schwarzenberger, Rafael ^a   Sayah Jeanne, Sakina ^b   Dubernet, Mathieu ^b   Walczak, Robert ^b   Hum, Dean W ^b   Schwartz, Stephanie ^a   Axt, Daisy ^a   Heneka, Michael T ^a,c  

^a UNIVERSITY OF BONN   (Germany)

^b Parc Eurasante Lille Metropole   (France)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer; Amyloid; Behavior; Inflammation; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID PRECURSOR PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PRESENILIN 1;

AGONISTS; ANIMAL; C57BL MOUSE; CHLOROCEBUS AETHIOPS; COGNITION DISORDERS; COS CELL LINE; FEMALE; GENETICS; MALE; MOUSE; PHYSIOLOGY; PLAQUE, AMYLOID; TRANSGENIC MOUSE; TREATMENT OUTCOME;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CERCOPITHECUS AETHIOPS; COGNITION DISORDERS; COS CELLS; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, AMYLOID; PPAR GAMMA; PRESENILIN-1; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84939876636     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8743-4     Document Type: Article

References (46)

1. Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–344. doi:10.1056/NEJMra0909142
2. Jack CR Jr, Knopman DS, Jagust WJ et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12:207–216. doi:10.1016/S1474-4422(12)70291-0
3. Palop JJ, Mucke L (2010) Amyloid-β induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci 13:812–818. doi:10.1038/nn.2583
4. Benilova I, Karran E, De Strooper B (2012) The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 15:349–357. doi:10.1038/nn.3028
5. In t’ Veld BA, Ruitenberg A, Hofman A et al (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345:1515–1521. doi:10.1056/NEJMoa010178
6. Heneka MT, Landreth GE, Feinstein DL (2001) Role for peroxisome proliferator-activated receptor-gamma in Alzheimer’s disease. Ann Neurol 49:276
7. Lehmann JM, Lenhard JM, Oliver BB et al (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406–3410
8. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82–86. doi:10.1038/34184
9. Ricote M, Li AC, Willson TM et al (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79–82. doi:10.1038/34178
10. Heneka MT, Landreth GE (2007) PPARs in the brain. Biochim Biophys Acta 1771:1031–1045. doi:10.1016/j.bbalip.2007.04.016
11. Yan Q, Zhang J, Liu H et al (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer’s disease. J Neurosci Off J Soc Neurosci 23:7504–7509
12. Heneka MT, Sastre M, Dumitrescu-Ozimek L et al (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain J Neurol 128:1442–1453. doi:10.1093/brain/awh452
13. Combs CK, Johnson DE, Karlo JC et al (2000) Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci Off J Soc Neurosci 20:558–567
14. Kim EJ, Kwon KJ, Park JY et al (2002) Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res 941:1–10
15. Luna-Medina R, Cortes-Canteli M, Alonso M et al (2005) Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem 280:21453–21462. doi:10.1074/jbc.M414390200
16. Sastre M, Dewachter I, Landreth GE et al (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci Off J Soc Neurosci 23:9796–9804
17. Sastre M, Dewachter I, Rossner S et al (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 103:443–448. doi:10.1073/pnas.0503839103
18. De la Monte SM, Tong M, Lester-Coll N et al (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease. J Alzheimers Dis JAD 10:89–109
19. Hiukka A, Maranghi M, Matikainen N, Taskinen M-R (2010) PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 6:454–463. doi:10.1038/nrendo.2010.89
20. Yin K-J, Deng Z, Hamblin M et al (2011) Vascular PPARδ protects against stroke-induced brain injury. Arterioscler Thromb Vasc Biol 31:574–581. doi:10.1161/ATVBAHA.110.221267
21. Polak PE, Kalinin S, Dello Russo C et al (2005) Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol 168:65–75. doi:10.1016/j.jneuroim.2005.07.006
22. Kalinin S, Richardson JC, Feinstein DL (2009) A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer’s disease. Curr Alzheimer Res 6:431–437
23. Iwashita A, Muramatsu Y, Yamazaki T et al (2007) Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J Pharmacol Exp Ther 320:1087–1096. doi:10.1124/jpet.106.115758
24. Paterniti I, Esposito E, Mazzon E et al (2010) Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury. J Pharmacol Exp Ther 333:465–477. doi:10.1124/jpet.110.165605
25. Jankowsky JL, Slunt HH, Ratovitski T et al (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17:157–165
26. Jardanhazi-Kurutz D, Kummer MP, Terwel D et al (2010) Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int 57:375–382. doi:10.1016/j.neuint.2010.02.001
27. Jäger S, Leuchtenberger S, Martin A et al (2009) Alpha-secretase mediated conversion of the Amyloid Precursor Protein derived membrane stub C99 to C83 limits Abeta generation. J Neurochem. doi:10.1111/j.1471-4159.2009.06420.x
28. Klunk WE, Bacskai BJ, Mathis CA et al (2002) Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 61:797–805
29. Wahle T, Thal DR, Sastre M et al (2006) GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. J Neurosci Off J Soc Neurosci 26:12838–12846. doi:10.1523/JNEUROSCI.1982-06.2006
30. Terwel D, Steffensen KR, Verghese PB et al (2011) Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. J Neurosci Off J Soc Neurosci 31:7049–7059. doi:10.1523/JNEUROSCI.6546-10.2011
31. Cramer PE, Cirrito JR, Wesson DW et al (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335:1503–1506. doi:10.1126/science.1217697
32. Diab A, Deng C, Smith JD et al (1950) (2002) Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol Baltim Md 168:2508–2515
33. Dehmer T, Heneka MT, Sastre M et al (2004) Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88:494–501
34. Hiatt WR, Kaul S, Smith RJ (2013) The cardiovascular safety of diabetes drugs—insights from the rosiglitazone experience. N Engl J Med 369:1285–1287. doi:10.1056/NEJMp1309610
35. Combs CK, Bates P, Karlo JC, Landreth GE (2001) Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem Int 39:449–457
36. Yamanaka M, Ishikawa T, Griep A et al (2012) PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci Off J Soc Neurosci 32:17321–17331. doi:10.1523/JNEUROSCI.1569-12.2012
37. Mawuenyega KG, Sigurdson W, Ovod V et al (2010) Decreased clearance of CNS β-amyloid in Alzheimer’s disease. Science 330:1774. doi:10.1126/science.1197623
38. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE (2009) CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci Off J Soc Neurosci 29:11982–11992. doi:10.1523/JNEUROSCI.3158-09.2009
39. Heneka MT, Sastre M, Dumitrescu-Ozimek L et al (2005) Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation 2:22. doi:10.1186/1742-2094-2-22
40. Kummer MP, Hermes M, Delekarte A et al (2011) Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. Neuron 71:833–844. doi:10.1016/j.neuron.2011.07.001
41. Daynes RA, Jones DC (2002) Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2:748–759. doi:10.1038/nri912
42. Devchand PR, Keller H, Peters JM et al (1996) The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384:39–43. doi:10.1038/384039a0
43. Pesant M, Sueur S, Dutartre P et al (2006) Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res 69:440–449. doi:10.1016/j.cardiores.2005.10.019
44. D’ Uscio LV, Das P, Santhanam AVR et al (2012) Activation of PPARδ prevents endothelial dysfunction induced by overexpression of amyloid-β precursor protein. Cardiovasc Res 96:504–512. doi:10.1093/cvr/cvs266
45. Nalbantoglu J, Tirado-Santiago G, Lahsaini A et al (1997) Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 387:500–505. doi:10.1038/387500a0
46. Walsh DM, Klyubin I, Fadeeva JV et al (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539. doi:10.1038/416535a